CS Pramesh discusses ten low-value or harmful practises that should be avoided in cancer care in India.

Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.

Anna Bibby joins The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.

Stein Kaasa and Jon Loge discuss their new Commission on palliative care.

Andre Ilbawi talks about his global analysis of available national cancer control plans with The Lancet Oncology.

A review in The Lancet Oncology asks whether patient reported outcomes in RCTs are consistent across their analysis, reporting, and interpretation. Author Madeline Pe discusses the findings.

Eva Steliarova-Foucher joins The Lancet Oncology to discuss the Europe-wide Automated Childhood Cancer Information System, and the increase in cancer incidence rates among children and adolescents.

Mark Souweidane joins The Lancet Oncology to discuss his dose-escalation study, assessing a convection-enhanced delivery for diffuse intrinsic pontine glioma.

Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.

Fabio Conforti talks to The Lancet Oncology about a meta-analysis showing that a patient's sex can affect the efficacy of cancer immunotherapy.

Paul Kluetz from the US FDA discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making.

Michael Hoeckel joins The Lancet Oncology to discuss his latest trial on the surgical treatment of vulvar carcinoma based on the theory of ontogenetic cancer fields.

Håvard Emil Danielsen joins The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.

Ross Camidge discusses RANO's papers on clinical trial design for patients with brain metastases.

John Field discusses a European position statement on lung cancer screening using low-dose CT.

Commission co-chairs Chi Van Dang and Elizabeth M. Jaffee discuss a new Lancet Oncology Commission on cancer treatment and care in the USA.

Ben Anderson talks about cancer care and cancer trends in Peru.

Ricky Sharma discusses results from three prospective trials on the use of selective internal radiotherapy for liver metastases from colorectal cancer.

Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.

Percy Lee discusses the impact of prior radiotherapy on the efficacy of pembrolizumab when used to treat non-small cell lung cancer.

Martin Taphoorn outlines the importance of palliative care for patients with gliomas.

Sandro Porceddu discusses the new Lancet Oncology Series on head and neck cancer.

Michele Cavo discusses the International Myeloma Working Group’s recommendations on the use of 18F-FDG PET/CT for patients with multiple myeloma and other plasma cell dyscrasias.

Lesley Seymour discusses the iRECIST guidelines for assessing tumour responses in immunotherapy trials.

Javier Torres-Roca and Louis Harrison join us to discuss their work on genome modelling and its uses in calculating the appropriate radiation dosage.

Ann Partridge talks about cancer survival in the USA.

Rafael Rossell discusses RET inhibitors and non-small cell lung cancer.

Brigitta Baumert discusses her article on quality of life in patients with high-risk, low-grade glioma.

Brian Rini discusses active surveillance for patients with metastatic renal cell carcinoma.

Shaji Kumar discusses updated consensus criteria from the International Myeloma Working Group for response and minimal residual disease assessment in multiple myeloma.

Catherine Sauvaget and Ryo Konno discuss Japan’s low uptake of screening programmes for breast and cervical cancer.

Anish Thomas discusses use of antibody-drug conjugates for cancer therapy.

Jean-Claude Dupont and François Doz discuss ethical issues in paediatric oncology clinical trials.

Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.

Sibylle Loibl discusses the findings and clinical implications of the GeparSepto trial.

Dr. Richard Carvajal discusses aspects of treatment and research for rare cancers.

Discussion of two new treatment approaches to indolent lymphoma and mantle-cell lymphoma, haematological diseases with generally poor response to chemotherapy.

Hideho Okada discusses immunotherapy response assessment criteria in neuro-oncology.

Rajendra Badwe discusses treatment options for metastatic breast cancer.

Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.

Ane Appelt discusses adopting a watchful waiting approach for patients with rectal cancer who achieved a clinical complete response after chemoradiotherapy.

Amy Kreimer discusses HPV vaccine dosing schedules and cervical cancer prevention.

Nancy Lin discusses RANO Group’s new response assessment criteria checklist.

Rolando Herrero summarises three papers that constitute the HPV and cancer Series.

Jeffery Weber discuses advances in cancer drug development.

Dr Saro Armenian discusses long term health concerns for survivors of childhood cancers.

Jeff Bradley discusses standard verses high-dose radiation in conjunction with chemotherapy for patients with phase III non-small-cell lung cancer.

Dennis Slamon discusses advances in breast cancer treatment based on data from the PALOMA trial.